Featured Clinical Trials

[email protected]

About this trial:

This study will evaluate zipalertinib, a novel EGFR tyrosine kinase inhibitor (TKI) versus placebo in participants with resected early-stage NSCLC harboring uncommon EGFRmt. An independent data monitoring committee (IDMC) will be established to monitor interim safety data.

Approximately 360 participants will be randomized to either receive zipalertinib or placebo. In Arm A: zipalertinib twice daily (BID) monotherapy OR Arm B: Placebo BID monotherapy.

Criteria for inclusion is outlined on the ct.gov website linked.
 

[email protected]

About this trial:

ALISCA-Lung2 is a clinical trial that is exploring whether an investigational medication called alisertib, when used in combination with paclitaxel, is safe and tolerable in patients with pathologically confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and an anti-PD-L1/PD-1 (immunotherapy) agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior treatment regimens. 

Eligible patients must be at least 18 years old and cannot have been treated with an aurora kinase A (AURKA) specific-targeted or pan-Aurora-targeted agent, including alisertib, or a taxane, including paclitaxel, in any setting. There are additional inclusion and exclusion criteria. The investigator at the study center will determine if you meet all of the criteria.

[email protected]

About this trial:

The TARGET-D 202 Phase 2 trial is evaluating the safety and efficacy (how well it works) of VS-7375, an investigational oral, KRAS G12D ON/OFF inhibitor. The trial is for people with previously treated, advanced non-small cell lung cancer (NSCLC) that has a specific gene mutation called KRAS G12D. Participants will be assigned to a trial group. All participants will receive VS-7375 as a pill on a daily schedule. One group that is being evaluated in the trial is people with asymptomatic, untreated brain metastases. The clinical trial team will explain the treatment plan for each participant. 

You may be able to take part if you:

• Are 18 years of age or older
• Have been diagnosed with unresectable (cannot be removed) locally advanced or metastatic (has spread from its original location to other parts of the body) non-small cell lung cancer with a KRAS G12D mutation
• Have at least one tumor that can be measured on a scan
• Have received prior treatment for advanced non-small cell lung cancer
   

Phone Number: 855.907.3286
Email: [email protected]

About this trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy given with chemotherapy compared to standard of care immunotherapy given with chemotherapy in people with extensive-stage small cell lung cancer who have not received prior treatment for advanced disease.

Participants who qualify will be assigned to receive one of the two treatment approaches.

The purpose of the study is to compare the safety and effectiveness of the investigational treatment and to help determine whether it may offer benefit for patients in the future.

Who can participate:

The study is open to patients with extensive-stage small cell lung cancer who have not received prior systemic treatment for advanced disease and are able to meet the study requirements.
 

Phone Number: 855.907.3286
Email: [email protected]

About the trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy combination given with chemotherapy compared to a standard immunotherapy plus chemotherapy in people with advanced or recurrent non small cell lung cancer (NSCLC) who have not received prior treatment for advanced disease. 

Participants who qualify will be assigned to receive one of the two options.

The purpose of the study is to compare the safety and effectiveness of these approaches and to help determine whether the investigational treatments may offer benefit for patients in the future.